← Back to home

HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT

Clinical trials for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT explained in plain language.

Never miss a new study

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT trials appear

Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New 5-Drug combo aims to tackle tough lymphoma

Disease control Recruiting now

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND/OR BCL2 AND/OR BCL6 REARRANGEMENT trials appear

New 5-Drug combo aims to tackle tough lymphoma